Glucagon-like peptide-1 (GLP-1): A gut hormone of potential interest in the treatment of diabetes

BioEssays

Volumn 20, Issue 8, 1998, Pages 642-651

  Ahrén, Bo ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; INSULIN; PEPTIDE FRAGMENT; PROGLUCAGON; PROTEIN PRECURSOR;

AMINO ACID SEQUENCE; ANIMAL; DIABETES MELLITUS; DRUG EFFECT; GENETICS; HUMAN; METABOLISM; MOLECULAR GENETICS; PANCREAS ISLET; PHYSIOLOGY; REVIEW; SECRETION; SIGNAL TRANSDUCTION;

ADENYLATE CYCLASE; AMINO ACID SEQUENCE; ANIMALS; DIABETES MELLITUS; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INSULIN; ISLETS OF LANGERHANS; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PROGLUCAGON; PROTEIN PRECURSORS; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 0032143876     PISSN: 02659247     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1521-1878(199808)20:8<642::AID-BIES7>3.0.CO;2-K     Document Type: Review

References (74)

1. Sutherland S, deDuve C (1948) Origin and distribution of the hyperglycemic glycogenolytic factor of the pancreas. J Biol Chem 175:663-674.
2. Polak JM, Bloom S, Coulling IU, Pearse AGE (1971) Immunofluorescent localization of enteroglucagon cells in the gastrointestinal tract of the dog. Gut 12:311-318.
3. Bell GI, Santerre RF, Mullenbach GT (1983) Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature 302:716-718.
4. Mojsov S, Heinrich G, Wilson IB, Ravazzola M, Orci L, Habener JF (1986) Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. J Biol Chem 261: 11880-11889.
5. Kreyman B, Ghatei MA, Williams G, Bloom SR (1987) Glucagon-like peptide-17-36: a physiological incretin in man. Lancet 2: 1300-1303.
6. Wettergren A, Scholdager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ (1993) Truncated GLP-1 (proglucagon 72-107 amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 38:665-673.
7. Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF (1987): Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in rat islet cell line. Proc Natl Acad Sci USA 84:3434-3438.
8. Thorens B (1992) Expression cloning of the pancreatic beta cell receptor of the gluco-incretin hormone glucagon-like peptide I. Proc Natl Acad Sci USA 89:8641-8645.
9. Gutniak M, Ørskov C, Holst JJ, Ahrén B, Efendic S (1992) Antidiabetogenic effect of glucagon-like peptide-1(7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med 326:1316-1322.
10. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CMB, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, Wilding JPH, Smith DM, Ghatei MA, Herbert J, Bloom SR (1996) A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379: 69-72.
11. Eissele R, Göke R, Willemer S, Harthus HP, Vermeer H, Arnold R, Göke B (1992) Glucagon-like peptide 1 cells in the gastrointestinal tract and pancreas of rat, pig, and man. Eur J Clin Invest 22:283-291.
12. Jin SL, Han VK, Simmons JG, Towle AC, Lauderm JM, Lund PK (1988) Distribution of glucagon-like peptide I (GLP I), glucagon, and glicentin in the rat brain: an immunocytochemical study. J Comp Neurol 271:519-532.
13. Holst JJ (1997) Enteroglucagon. Annu Rev Physiol 57:257-271.
14. White JW, Saunders GF (1986) Structure of the human glucagon gene, Nucleic Acids Res 14:4719-4730.
15. Bell GI, Sanchez-Pescador R, Laybourn PJ, Najarian RC (1983) Exon duplication and divergence in the human preproglucagon gene. Nature 304:368-371.
16. Novak U, Wilks A, Buell G, McEwen S (1987) Identical mRNA for preproglucagon in pancreas and gut. Eur J Biochem 164:553-558.
17. Drucker DJ, Brubaker PL (1989) Proglucagon gene expression is regulated by a cyclic AMP-dependent pathway in rat intestine. Proc Natl Acad Sci USA 86:3953-3957.
18. Holst JJ, Hansen L, Deacon CF (1997) The GLP-1 receptor antagonist, GLP-1 (9-36amide), is a primary product of the intestinal L-cell. Diabetologia 40:suppl 1, A27.
19. Rouillé Y, Martin S, Steiner DF (1995) Differential processing of proglucagon by the subtilisin-like prohormone convertases PC2 and PC3 to generate either glucagon or glucagon-like peptide. J Biol Chem 870:26488-26496.
20. Göke B, Göke R, Fehmann HC, Bode HP (1996) Physiology and pathophysiology of GLP-1, In: Fehmann HC, Göke B (eds): The Insulinotropic Gut Hormone Glucagon-Like Peptide-1, Frontiers in Diabetes. Basel: Karger, pp. 275-309.
21. Thornton K, Gorenstein DG (1994) Structure of glucagon-like peptide (7-36)amide in a dodecylphosphocholine micelle as determined by 2D NMR. Biochemistry 33:3532-3539.
22. Gefel D, Hendrick GK, Mojsov S, Habener JF, Weir GC (1990) Glucagon-like peptide-I analogs: effects on insulin secretion and adenosine 3′5′-monophosphate formation. Endocrinology 126:2164-2168.
23. Ahrén B, Larsson H, Holst JJ (1997) Reduced gastric inhibitory polypeptide but normal glucagon-like peptide 1 response to oral glucose in postmenopausal women with impaired glucose tolerance. Eur J Endocrinol 137:127-131.
24. Miholic J, Ørskov C, Holst JJ, Kotzer H, Meyer HJ (1991) Emptying of the gastric substitute, glucagon-like peptide-1 (GLP-1), and reactive hypoglycemia after total gastrectomy. Dig Dis Sci 36:1361-1370.
25. Sugiyama K, Manaka H, Kato T, Yamatani K, Tominaga M, Sasaki H (1994) Stimulation of truncated glucagon-like peptide-1 release from the isolated perfused canine ileum by glucose absorption. Digestion 55:24-28.
26. Manaka H, Sugiyama K, Hama K, Yamatani K, Sasaki H (1997) Glucose absorption and GLP-1 secretion. Diabetologia 40:suppl 1: A129.
27. Brubaker PL (1991) Regulation of intestinal proglucagon-derived peptide secretion by intestinal regulatory peptides. Endocrinology 128:3175-3182.
28. Mentlein R, Gallwitz B, Schmidt W (1993) Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7-36)amide, peptide histidine methionine and is responsible for their degradation in serum. Eur J Biochem 214:829-835.
29. Ørskov C, Andreasen J, Holst JJ (1992) All products of proglucagon are elevated in plasma from uremic patients. J Clin Endocrinol Metab 74:379-384.
30. Göke R, Conlon JM (1988) Receptors for glucagon-like peptide-1(7-36)amide on rat insulinoma-derived cells. J Endocrinol 116:357-362.
31. Thorens B, Porret A, Bühler L, Deng SP, Morel P, Widmann C (1993) Cloning and functional expression of the human islet GLP-1 receptor, Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes 42:1678-1682.
32. Wess J (1997) G-protein-coupled receptors: molecular mechanisms involved in receptor activation and selectivity of G-protein recognition. FASEB J 11:346-354.
33. Göke R, Richter G, Göke B, Trautmann M, Arnold R (1989) Internalization of glucagon-like peptide-1(7-36)amide in rat insulinoma cells. Res Exp Med 189:257-264.
34. Alvarez E, Roncero I, Chowen JA, Thorens B, Blazquez E (1996) Gene expression of the rat glucagon-like peptide-1 (GLP-1) receptor in rat brain. J Neurochem 66: 920-927.
35. Stoffel M, Espinos III R, Le Beau MM, Bell GI (1993) Human glucagon-like peptide-1 receptor gene. Localization to chromosome band 6p21 by fluorescence in situ hybridization and linkage of a highly polymorphic simple tandem repeat DNA polymorphism to other markers on chromosome 6. Diabetes 42:1215-1218.
36. Abrahamsen N, Nishimura E (1995) Regulation of glucagon and glucagon-like peptide-1 receptor messenger ribonucleic acid expression in cultured rat pancreatic islets by glucose, cyclic adenosine 3′5′-monophosphate, and glucocorticoids. Endocrinology 135: 1572-1578.
37. Holst JJ, Ørskov AC, Schwartz TW, Nielsen OV (1987) Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut. FEBS Lett 211:169-174.
38. Fridolf T, Böttcher G, Sundler F, Ahrén B (1991) GLP-1 and GLP-1(7-36) amide: Influences on basal and stimulated insulin and glucagon secretion in the mouse. Pancreas 6:208-215.
39. Fridolf T, Ahrén B (1991) GLP-1(7-36) amide stimulates insulin secretion in rat islets: studies on the mode of action. Diabet Res 16:185-191.
40. van Dijk G, Lindskog S, Holst JJ, Steffens AB, Ahrén B (1996) Effects of glucagon-like peptide-I on glucose turnover in rats. Am J Physiol 270:E1015-E1021.
41. Ahrén B (1995) Insulinotropic action of truncated glucagon-like peptide-1 in mice. Acta Physiol Scand 153:205-206.
42. Ahrén B, Gutniak M (1997) No correlation between insulin and islet amyloid polypeptide (IAPP) after stimulation with glucagon-like peptide-1 (GLP-1) in type 2 diabetes. Eur J Endocrinol 137:643-649.
43. Kolligs F, Fehmann HC, Göke R, Göke B (1995) Reduction of the incretin effect in rats by the glucagon-like peptide-1 receptor antagonist exendin (9-39) amide. Diabetes 44:16-19.
44. Scrocchi LA, Brown TJ, MacLusky N, Brubaker PL, Auerbach AB, Joyner AL, Drucker DJ (1996) Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nature Med 2: 1254-1258.
45. Ørskow C, Holst JJ, Nielsen OV (1988) Effect of truncated glucagon-like peptide-1 (proglucagon 78-107amide) on endocrine secretion from pig pancreas, antrum and stomach. Endocrinology 123:2009-2013.
46. Ahrén B, Gingerich RL, Havel PJ (1995) Effects of cholecystokinin and glucagon-like peptide 1 on the secretion of pancreatic polypeptide in mice. Regul Pept 59:297-302.
47. Moens K, Heimberg H, Flamez D, Huypens P, Quartier E, Ling Z, Pipeleers D, Gremlich S, Thorens B, Schuit F (1996) Expresion and functional activity of glucagon, glucagon-like peptide I and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells. Diabetes 45:257-261.
48. Heller RS, Kieffer TJ, Habener JF (1997) Insulinotropic glucagon-like peptide I receptor expression in glucagon-producing α-cells of the rat endocrine pancreas. Diabetes 46:785-791.
49. Fehmann HC, Habener JF (1991) Functional receptors for the insulinotropic hormone glucagon-like peptide-1(7-37) on a somatostatin secreting cell line. FEBS Lett 279:335-340.
50. Nauck MA, Kleine N, Ørskov C, Holst JJ, Willms B, Creutzfeldt W (1993) Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36:741-744.
51. Larsson H, Holst JJ, Ahrén B (1997) Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans. Acta Physiol Scand 160:413-422.
52. D'Alessio D, Kahn SE, Leusner C, Ensinck JW (1994) Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Endocrinol Metab 93:2263-2266.
53. Ørskov L, Holst JJ, Møller J, Ørskov C, Møller N, Alberti KGMM, Schmitz O (1996) GLP-1 does not acutely affect insulin sensitivity in healthy man. Diabetologia 39:1227-1232.
54. Ahrén B, Larsson H, Holst JJ (1997) Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 82:473-478.
55. 2: a physiological inhibitor of gastric acid secretion in man. J Endocrinol 126:169-173.
56. Wettergren A, Wøjdemann M, Meisner S, Stadil F, Holst JJ (1997) The inhibitory effect of glucagon-like peptide-1 7-36amide on gastric acid secretion in man depends on an intact vagal innervation. Gut 40:597-601.
57. Layer P, Holst JJ (1993) GLP-1: a humoral mediator of the ileal brake in humans? Digestion 54:385-386.
58. Tang-Christensen M, Larsen PJ, Göke R, Fink-Jensen A, Jessop DS, Møller M, Sheikh SP (1996) Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol 271:R848-R856.
59. Ørskov C, Poulsen SS, Møller M, Holst JJ (1996) Glucagon-like peptide-1 receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide 1. Diabetes 45:832-835.
60. 2+-signaling pathway in pancreatic beta-cells by the insulinotropic hormone glucagon-like peptide-1. J Biol Chem 270:17749-17757.
61. Fridolf T, Ahrén B (1993) Effects of glucagon-like peptide-1(7-36)amide on the cytoplasmic calcium concentration in rat islet cells. Mol Cell Endocrinol 96:85-90.
62. Ahrén B, Simonsson E, Karlsson S (1996) Glucagon-like peptide-1(7-36)amide and cytoplasmic calcium in insulin producing cells. Acta Physiol Scand 157:333-341.
63. Holz GG, Kühtreiber WM, Habener JF (1993) Pancreatic β-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-I(7-37). Nature 361:362-365.
64. Gromada J, Dissing S, Bokvist K, Renström E, Frøkjär-Jensen J, Wulff BS, Rorsman P (1995) Glucagon-like peptide I increases cytoplasmic calcium in insulin-secreting βTC3-cells by enhancement of intracellular calcium mobilization. Diabetes 44:767-774.
65. Zawalich WS, Zawalich KC, Rasmussen H (1993) Influence of glucagon-like petide-1 on β-cell responsiveness. Regul Pept 44:277-283.
66. Nauck MA, Heimesaat MM, Øskov C, Holst JJ, Ebert R, Creutzfeldt W (1993) Preserved incretin activity of GLP-1 (7-36amide) but not of synthetic human GIP in patients with type 2 diabetes mellitus. J Clin Invest 91:301-307.
67. Vaag AA, Holst JJ, Völund A, Beck-Nielsen HB (1996) Gut incretin hormones in identical twins discordant for non-insulin diabetes mellitus (NIDDM) - evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins. Eur J Endocrinol 135:425-432.
68. Eissele R, Göke R, Weichhardt U, Ferhmann HC, Arnold R, Göke B (1994) Glucagon-like peptide 1 immunoreactivity in gastroenteropancreatic endocrine tumors: a light-and electron-microscopic study. Cell Tissue Res 276:571-580.
69. Nathan DM, Schreiber E, Mojsov S, Habener JF (1992) Insulinotropic action of glucagonlike peptide-1-(7-37) in diabetic and nondiabetic subjects. Diabetes Care 15:270-276.
70. Rachman J, Barrow BA, Levy JC, Turner RC (1997) Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia 40:205-211.
71. Juntti-Berggren L, Pigon J, Karpe F, Hamsten A, Gutniak M, Vignati L, Efendic S (1996) The antidiabetogenic effect of GLP-1 is maintained during a 7-day treatment period and improves diabetic dyslipoproteinemia in NIDDM patients. Diabetes Care 19:1200-1206.
72. Ritzel R, Ørskov C, Holst JJ, Nauck MA (1995) Pharmacokinetic insulinotropic, and glucagonostatic properties of GLP-1(7-36 amide) after subcutaneous injection in healthy volunteers, Dose-response relationships. Diabetologia 38:720-725.
73. Gutniak MK, Larsson H, Heiber SJ, Juneskans OT, Holst JJ, Ahrén B (1996) Potential therapeutic levels of glucagon-like peptide-1 achieved in humans by a buccal tablet. Diabetes Care 19:843-848.
74. Gutniak MK, Larsson H, Saunders SW, Juneskans O, Holst JJ, Ahrén B (1997) GLP-1 tablet in NIDDM in fasting and postprandial conditions. Diabetes Care 20:1874-1879.